SEC Form 4 · accession 0001171000-16-000118
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ashraf Hanna
Director
Period of report
Mar 31, 2016
Accepted (ET)
Apr 4, 2016 · 6:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Mar 31, 2016 | M | 500 | $0.125 | A | 6,320 | D | |
| Ordinary Shares | holding | — | — | — | 1,500 | I | By Ashraf E. Hanna Living Family Trust U/A 8/20/15 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1 | $0.125 | Mar 31, 2016 | M | 500 | D | Mar 31, 2016 | Jul 1, 2019 | Ordinary Shares | 500 | 2,500 | D |
Explanation of responses
- F1500 of the Restricted Share Units vested and became convertible on 3/31/16, and 500 Restricted Share Units shall vest and become convertible on each of 6/30/16, 9/30/16, 12/31/16, 3/31/17 and 6/30/17, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.